Evidence map›Paper›PMID 33277615›Full record

ArticleCancer gene therapy2021

Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis.

Xiaoming Liu, Dandan Peng, Yixin Cao, Yuanzhe Zhu, Jianjun Yin, Guangxing Zhang, Xiaodong Peng, Yanqiu Meng

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Making Sense of Antisense lncRNAs in Hepatocellular Carcinoma.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.Frontiers in cell and developmental biology · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaoming Liu *Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, 330006, Nanchang, P.R. China.
Dandan Peng *Department of Radiotherapy, General Hospital of Pingmei Shenma Medical Group, 450000, Pingdingshan, P.R. China.
Yixin CaoDepartment of Oncology, The First Affiliated Hospital of Nanchang University, 330006, Nanchang, P.R. China.
Yuanzhe ZhuDepartment of Oncology, The First Affiliated Hospital of Nanchang University, 330006, Nanchang, P.R. China.
Jianjun YinDepartment of Oncology, Yugan Renhe Hospital, 335100, Shangrao, P.R. China.
Guangxing ZhangGraduate School of Medicine, Nanchang University, Nanchang, P.R. China.
Xiaodong PengDepartment of Oncology, The First Affiliated Hospital of Nanchang University, 330006, Nanchang, P.R. China. pxddhbb@163.com.ORCID http://orcid.org/0000-0002-8441-0490
Yanqiu MengDepartment of Oncology, The First Affiliated Hospital of Nanchang University, 330006, Nanchang, P.R. China. 18772101281@139.com.
Nanchang University · CNShenhua Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have illustrated the role of aberrant regulatory interactions in the mediation of malignant phenotypes of cancer cells, which could potentially provide novel therapeutic targets to limit the destructive recurrence and metastasis of hepatocellular carcinoma (HCC). Herein, we clarify the oncogenic role of the long noncoding RNA (lncRNA) distal-less homeobox 6 antisense 1 (DLX6-AS1) in HCC in vivo and in vitro. To this end, we knocked down lncRNA DLX6-AS1 and manipulated the expression of miR-513c to characterize their effects in HCC cell viability, migration, invasion, and apoptosis. Furthermore, we probed the interactions with miR-513c's target gene Cullin4A (Cul4A) and the degradation of Annexin A10 (ANXA10) protein. Our data show that lncRNA DLX6-AS1 and Cul4A were highly expressed, while miR-513c and ANXA10 were poorly expressed in HCC tissues and cells. Moreover, the silencing of lncRNA DLX6-AS1 impeded the viability, invasion, and migration of HCC cells, while stimulating cell apoptosis. Further data indicated that lncRNA DLX6-AS1 targeted and repressed miR-513c expression, where the tumor-inhibiting effects of lncRNA DLX6-AS1 silencing was achieved by elevating miR-513c expression. Importantly, the lncRNA DLX6-AS1 upregulated the expression of Cul4A through sponging of miR-513c. The silencing of Cul4A restricted the malignant phenotypes of HCC cells by repressing the ubiquitination-mediated degradation of ANXA10. In vivo experiments verified that lncRNA DLX6-AS1 promoted the progression of HCC through the miR-513c/Cul4A/ANXA10 axis. Thus, the silencing of lncRNA DLX6-AS1 impaired miR-513c-dependent Cul4A inhibition and subsequently elevated ubiquitination-mediated degradation of ANXA10, thereby preventing the occurrence and development of HCC.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAnimalsAnnexinsApoptosisCarcinoma, HepatocellularCell ProliferationCullin ProteinsFemaleHomeodomain ProteinsHumansLiver NeoplasmsMaleMiceMice, Inbred BALB CAnnexinsANXA10 protein, humanCUL4A protein, humanCullin ProteinsDLX6 protein, humanHomeodomain ProteinsMicroRNAsMIRN513A1 microRNA, humanRNA, AntisenseRNA, Long Noncoding

Identifiers

PMID33277615
OpenAlexW3107057855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.